Background: Despite the absence of a relationship between cholesterol and abdominal aortic aneurysm (AAA) expansion, there is evidence from a number of studies to suggest that statin therapy may influence AAA expansion, presumably through pleiotropic effects. To confirm whether statin therapy is associated with less AAA expansion, we performed a meta-analysis of clinical controlled studies of statin therapy for prevention of AAA expansion. Methods: To identify all clinical studies of statin therapy vs control (no statins) enrolling patients with small (<55 mm) AAA, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. For each study, data regarding AAA expansion in both the statin and control groups were used to generate standardized mean differences (SMDs; <0 favoring statin therapy; >0 favoring control) and 95% confidence intervals (CIs). Study-specific estimates were combined using inverse variance-weighted averages of logarithmic SMDs in fixed-effects and random-effects models. Results: We identified five clinical controlled studies of statin therapy vs control enrolling patients with small AAA, including no randomized and five observational studies. Our meta-analysis included data on 697 patients with small AAA received statin therapy or no statins. Pooled analysis demonstrated that statin therapy was statistically significantly associated with less expansion rates (random-effects SMD, ؊0.50; 95% CI, ؊0.75 to ؊0.25; P ‫؍‬ .0001). There was statistically significant trial heterogeneity of results (P ‫؍‬ .03). Exclusion of any single trial from the analysis did not substantively alter the overall result of our analysis. There was no evidence of significant publication bias (P ‫؍‬ .81). 
Although several studies have found an association between the presence of abdominal aortic aneurysm (AAA) and the concentration of total cholesterol, 1, 2 there is no clear relationship between total cholesterol and AAA expansion. 3, 4 Despite the absence of a relationship between cholesterol and AAA expansion, there is evidence from a number of studies to suggest that statin therapy may be associated with less AAA expansion, presumably through its pleiotropic effects. 5 A meta-analysis by Guessous et al 6 of two cohort studies 7, 8 found statin therapy appeared to hold promise for being associated with less AAA expansion. Our preliminary meta-analysis 9 of three observational clinical studies 8, 10, 11 also suggested that statin therapy was associated with less AAA expansion. Since these meta-analyses 6, 9 were conducted, however, a number of clinical studies have provided the association of statin therapy on less AAA expansion. To confirm whether statin therapy is associated with less AAA expansion, we performed an updated metaanalysis of clinical controlled studies of statin therapy for prevention of AAA expansion.
METHODS

Search strategy.
All clinical studies of statin therapy vs control (no statins) that enrolled patients with small AAA were identified using a two-level search strategy. First, public domain databases, including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, were searched using Web-based search engines (PubMed, OVID). Second, relevant studies were identified through a manual search of secondary sources, including references of initially identified articles and a search of reviews and commentaries. All references were downloaded for consolidation, elimination of duplicates, and further analysis. Study selection and data abstraction. Studies considered for inclusion met the following criteria: the design was a clinical controlled study, the study population comprised patients with small (Յ55-mm) AAA, patients received statin therapy vs no statins (control), and main outcomes included AAA expansion. We included not only studies providing expansion rates adjusted for potentially confounding variables but also studies reporting unadjusted expansion rates. A Quality of Reporting of Metaanalyses (QUOROM) 12 flow diagram of the study selection process is illustrated in Fig 1. Data regarding detailed inclusion criteria, statin type, duration of follow-up, and AAA expansion were abstracted (as available) from each individual study. According to the guidance to authors for the preparation of Cochrane Intervention reviews, 13 we imputed missing data (means and standard deviations [SDs]) of expansion rates.
Statistical analysis. For each study, AAA expansion data in the statin and control groups were used to generate standardized mean differences (SMDs; Ͻ0 favors statin therapy; Ͼ0 favors control) and 95% confidence intervals (CIs). Study-specific estimates were combined using inverse variance-weighted averages of logarithmic SMDs in both fixed-effects and random-effects models. Betweenstudy heterogeneity was analyzed by means of standard 2 tests. Where no significant statistical heterogeneity was identified, the fixed-effects estimate was used preferentially as the summary measure. Sensitivity analyses were performed to assess the contribution of each study to the pooled estimate by excluding individual studies one at a time and recalculating the pooled SMD estimates for the remaining studies (leave-one-out meta-analysis). To assess the effect of qualitative heterogeneity in study design on the pooled effect estimate, the effects of statin therapy on AAA expansion were explored separately in studies providing adjusted and unadjusted expansion rates. Publication bias was assessed graphically using a funnel plot and mathematically using an adjusted rank correlation test.
14 All analyses were conducted using Review Manager 5.0, 15 Comprehensive Meta-Analysis 2 (Biostat, Englewood, NJ), and Meta-Analyst 3.0 software. Fig 1, our search identified five clinical controlled studies 7, 8, 10, 11, 17 of statin therapy vs control that enrolled patients with small AAA. These included no randomized and five observational studies. Our meta-analysis included data on 697 patients with small AAA received statin therapy or no statins. The baseline characteristics for the patients enrolled in each study are summarized in the Table. Sukhija et al 7 reported the size of AAAs at long-term follow-up in 130 patients with AAAs who were not treated surgically and in those treated with and without statins. At long-term follow-up of patients treated with statins, serum low-density lipoprotein cholesterol decreased from 142 Ϯ 18 to 90 Ϯ 17 mg/dL (P Ͻ .001), serum high-density lipoprotein cholesterol increased from 43 Ϯ 6 to 46 Ϯ 6 mg/dL (P Ͻ .001), and serum triglycerides decreased from 137 Ϯ 19 to 120 Ϯ 20 mg/dL (P Ͻ .001). AAA sizes were measured by computed tomography (CT) scans at baseline and at the last follow-up and were 46 Ϯ 6 mm at baseline and 45 Ϯ 6 mm at the 23 Ϯ 7-month follow-up in patients treated with statins (P ϭ NS) and 45 Ϯ 6 mm at baseline and 53 Ϯ 6 mm at the 24 Ϯ 7-month follow-up in patients not treated with statins (P Ͻ .001). Mortality at long-term follow-up was 5% (45 Ϯ 8 months) in patients with AAAs treated with statins and 16% (44 Ϯ 8 months) in those without statin treatment (P Ͻ .05).
16
RESULTS
As outlined in
A retrospective analysis by Schouten et al 8 included 150 patients under surveillance with a follow-up (every 6 to 12 months by means of ultrasound imaging) for aneurysm expansion of at least 12 months and a minimum of three diameter evaluations. Multiple regression analysis (age, gender, AAA diameter at initial presentation, nonsteroidal anti-inflammatory drug use, statin use, and cardiovascular risk factors were used as independent variables), weighted with the number of observations (ie, number of ultrasound measurements), was performed to test the influence of statins on AAA expansion rate. Statin users had a mean 11 included 121 patients with a Ն30-mm AAA undergoing ultrasound surveillance (at 3-to 12-month intervals according to AAA diameter and patients' conditions) for at least 1 year. The mean aneurysm expansion rate did not differ between patients treated and not treated with statins (1.9 Ϯ 1.8 mm/y vs 2.6 Ϯ 2.4 mm/y, P ϭ .27). In a study by Karlsson et al, 17 213 patients with a 35 to 49-mm AAA were followed-up with ultrasound examination every 6 months for a minimum of 18 months. Patients receiving statin medication had a lower median expansion rate than patients not taking statins of 1.6 vs 2.5 mm/y (95% CI for the difference, 0.03-1.5 mm/y; P ϭ .008).
Although Sukhija 17 provided a median instead of a mean and a 95% CI instead of a SD. According to the guidance to authors for the preparation of Cochrane Intervention reviews, 13 we imputed a missing mean in the study by Karlsson et al 17 and missing SDs in the studies by Schouten et al, 8 Schlösser et al, 10 and Karlsson et al. 17 Pooled analysis demonstrated statistically significantly lower expansion rates with statin therapy (random-effects SMD, Ϫ0.50; 95% CI, Ϫ0.75 to Ϫ0.25; P ϭ .0001; Fig 2) . There was statistically significant trial heterogeneity of results (P ϭ .03). When data from studies providing adjusted and unadjusted expansion rates were separately pooled, statin therapy was associated with lower expansion rates that remained statistically significant for adjusted studies (fixed-effects SMD, Ϫ0.40; 95% CI, Ϫ0.63 to Ϫ0.17; P ϭ .0006; P for heterogeneity ϭ .87) and for unadjusted studies (random-effects SMD, Ϫ0.58; 95% CI, Ϫ1.04 to Ϫ0.12; P ϭ .01; P for heterogeneity ϭ .008). Exclusion of any single trial from the analysis (leave-one-out meta-analysis) did not substantively alter the overall result of our analysis (Fig 3) .
To assess publication bias, we generated a funnel plot of the effect size vs the reciprocal of the standard error for each study (Fig 4) . Although the adjusted rank correlation test 14 did not indicate publication bias (P ϭ .81), there is clearly limited power to detect such bias and accordingly it is difficult to assess, given the small number of only five studies examined. 
DISCUSSION
Our analysis showed that statin therapy was associated with lower expansion rates in patients with small AAA, which suggests that statins may reduce AAA expansion. Despite the absence of a clear relationship between serum cholesterol level and AAA expansion, statin therapy is expected to prevent AAA development because the pleiotropic effects of statins include an anti-inflammatory effect, antioxidative effect, and the reduction of matrix metalloproteinase (MMP) secretion. 18 Statins reduce the tissue levels of MMP-9 in human AAA specimens explanted for culture.
Nagashima et al 19 suggested that cerivastatin could directly modulate the biology of the AAA wall and suppressed MMP-9 production in the AAA wall by inhibiting the activation of neutrophils and macrophages. Evans et al 20 demonstrated a reduction in MMP-9 levels in the AAA wall in patients randomized to simvastatin. Furthermore, Wilson et al 21 showed that simvastatin, pravastatin, and atorvastatin decreased concentrations of MMP-3 and MMP-9 in the anterior AAA wall of humans undergoing asymptomatic repair. In experimental studies, simvastatin suppressed AAA progression in a mouse model, accompanied by a reduction of MMP-9 and an increase of tissue inhibitors of metalloproteinase-1, whereas inflammatory cell infiltration was not inhibited. 22, 23 Shiraya et al 24 demonstrated an inhibitory effect of atorvastatin in an elastase-induced rat AAA model. However, atorvastatin suppressed macrophage recruitment into the vascular wall through the inhibition of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 expression, leading to the inhibition of MMP-12, but not MMP-9 expression. Therefore, it is suggested that the suppression of AAA development by atorvastatin was mainly dependent on its anti-inflammatory effect. 18 Karlsson et al 25 demonstrated that patients taking acetylsalicylic acid (ASA) had lower expansion rates than those not taking ASA (0.18 vs 0.26 cm/y, P ϭ .004) and that patients taking statins and ASA together had a significantly reduced expansion rate than patients who did not take statins or ASA (0.14 vs 0.27 cm/y, P Ͻ .001). Statins and ASA have different anti-inflammatory properties, which might explain the complementary effect, although ASA seems to be more effective than statins (0.19 vs 0.23 cm/y).
Meanwhile, an association of oxidative stress with the formation of AAA has been suggested. Reactive oxygen and nitrogen species are increased in the human aneurysmal wall compared with the normal aorta and adjacent nonaneurysmal aortic wall. 26 Overexpressed reactive oxygen species and nitric oxide increased the expression of MMPs through the activation of nuclear factor B and induced apoptosis of vascular smooth muscle cells in the aneurysm wall. [27] [28] [29] Statins may improve endothelial function through their antioxidant effects.
The results of the present meta-analysis are consistent with and strengthen those of previous meta-analyses. 6, 9 Pooled results of two cohort studies 7, 8 in the meta-analysis by Guessous et al, 6 representing 280 patients, showed a significant decrease of expansion rate, with a fixed-effects mean difference (MD) of Ϫ2.97 mm/y (95% CI, Ϫ5.83 to Ϫ0.11 mm/y). Pooled analysis of three observational clinical studies 8, 10, 11 in our preliminary meta-analysis, 9 representing 418 patients, also demonstrated a significant reduction in expansion rate with statin therapy relative to control, with a random-effects MD of Ϫ1.00 mm/y (95% CI, Ϫ1.54 to Ϫ0.47 mm/y; P ϭ .0002).
In the present meta-analysis, we combined five studies, representing 697 patients, and the pooled result was robust in sensitivity analyses. Although the SMDs of AAA expansion rates were similar (Ϫ0.41 to Ϫ0.31) in four 8, 10, 11, 17 of the five studies included in the present meta-analysis, only the study by Sukhija et al 7 provided Ϫ1.06 of the SMD. The mean or median diameters of the baseline AAA were Յ40 mm in the four studies, 8, 10, 11, 17 but in the study by Sukhija et al, 7 the mean diameter was 46 mm in the statin group and 45 mm in the control group. These findings suggest that the inhibitory effect of statin therapy for AAA expansion may depend on the diameter of AAA.
Our analysis, however, must be viewed in the context of its limitations. The major limitation of our study is that we combined only observational studies, and therefore, the treatment strategy was not based on randomized assignment. Our findings are subject to selection bias and confounding. To minimize these biases, Schouten et al 8 and Schlösser et al 10 used a multivariate linear regression model and provided not unadjusted but adjusted effect estimates. Nevertheless, hidden bias may remain because of the influence of unmeasured confounders. The other three studies 7, 11, 17 provided only unadjusted effect estimates. In nonrandomized observational studies, it is always necessary to adjust for confounding, otherwise the results are subject to some degree of bias. To confirm our results and more accurately assess the effect of statins on AAA expansion, a large randomized trial is needed. Because most patients with AAA may have indications for statin therapy, they are evaluated for these indications and statin therapy should be started if such indications are present. In the absence of any indications for statin therapy, the use of statins could be considered based on what appears to be a modest inhibitory effect on aneurysm expansion. 
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